22917-85-7

Basic information

• Product Name: 2-amino-9-propyl-3,9-dihydro-6H-purin-6-one
• Synonyms: 2-Amino-9-propyl-1,9-dihydro-6H-purin-6-one; 2-amino-9-propyl-9H-purin-6-ol; 6H-purin-6-one, 2-amino-1,9-dihydro-9-propyl-; 9H-purin-6-ol, 2-amino-9-propyl-
• CAS NO: 22917-85-7
• Molecular Formula: C₈H₁₁N₅O
• Molecular Weight: 193.2058
• Mol File: 22917-85-7.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 479.5°C at 760 mmHg
• Flash Point: 243.8°C
• Density: 1.57g/cm³
• Vapor Pressure: 2.36E-09mmHg at 25°C
• Refractive Index: 1.752
• CAS DataBase Reference: 2-amino-9-propyl-3,9-dihydro-6H-purin-6-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-9-propyl-3,9-dihydro-6H-purin-6-one(22917-85-7)
• EPA Substance Registry System: 2-amino-9-propyl-3,9-dihydro-6H-purin-6-one(22917-85-7)

Safety Data

• Hazardous Substances Data: 22917-85-7(Hazardous Substances Data)

Usage

Chemical compound

2-amino-9-propyl-3,9-dihydro-6H-purin-6-one

Classification

Purine derivative

Functional groups

Propyl group and amino group attached to the purine ring

Applications

Pharmaceuticals, synthesis of drugs and therapeutic compounds

Additional potential activities

Biological and pharmacological activities

Upstream product

• 10310-21-1 2-Amino-6-chloropurin 
• 64-18-6 formic acid 
• 77287-34-4 formamide 
• 145785-30-4 2-Amino-5-nitroso-6-propylamino-3H-pyrimidin-4-one 
• 131490-65-8 5-<amino>-1-propyl-1H-imidazole-4-carboxamide 
• 61507-88-8 5-amino-1-propyl-1H-imidazole-4-carboxamide 
• 90000-49-0 2-amino-6-(n-propylamino)pyrimidin-4(3H)-one 
• 306302-08-9 2-amino-6-(1,2,4-triazol-4-yl)-9-H-purine 
• 1904-98-9 2,6-diaminopurine 
• 131490-69-2 1-propyl-5-<(thiocarbamoyl)amino>-1H-imidazole-4-carboxamide 

Relevant articles and documents

The discovery of purine-based agents targeting triple-negative breast cancer and the αB-crystallin/VEGF protein–protein interaction

Oestrogen receptor-negative breast cancer, particularly subtypes such as triple-negative breast cancer (TNBC, around 10–15% of cases), are characterised by poor long-term survival, poor response to therapy and early progression to metastasis. Purine-based compounds represent a privileged scaffold in anticancer drug design, with several clinically approved and experimental agents in clinical development comprising a purine core structure. In this study, a series of new purine-based compounds were synthesised; seven of the new analogues were found to significantly reduce the in vitro viability of TNBC cell lines (MDA-MB-231 and MDA-MB-436) with IC50 values of ≤50 μM. In previous work, we have proposed a new concept for targeting angiogenesis driving TNBC progression, by disrupting the protein–protein interaction between the molecular chaperone αB-crystallin (CRYAB) and VEGF. Since previous clinical studies applying anti-VEGF therapy to TNBC patients have met with limited success, we were interested to test our most promising purine analogues against CRYAB/VEGF, using a custom-designed cell-based CRYAB/VEGF165 interaction assay platform. Analogues 4e and 4f significantly reduced the interaction between CRYAB/VEGF165, and compound 4e (100 μM) was also found to decrease the levels of soluble VEGF expressed by MDA-MB-231 cells by 40%. In conclusion, these promising early activity profiles warrant further investigation to validate this concept.

HETEROCYCLIC GTP CYCLOHYDROLASE 1 INHIBITORS FOR THE TREATMENT OF PAIN

The present invention relates to the field of small molecule heterocyclic inhibitors of GTP cyclohydrolase (GCH-I), or a tautomer, prodrug, or pharmaceutically acceptable salt thereof. The invention also features pharmaceutical compositions of the compounds and the medical use of these compounds for the treatment or prevention of pain (e.g., inflammatory pain, nociceptive pain, functional pain, or neuropathic pain).

Alkylpurines as immunopotentiating agents. Synthesis and antiviral activity of certain alkylguanines.

Several simple 8-substituted 9-alkyl- and 7,8-disubstituted 9-alkylguanine derivatives were synthesized as potential antiviral agents. These were tested for antiviral protection against a lethal Semliki Forest virus (SFV) infection in mice, and their anti